Minerva Neurosciences Reports Q3 2025 Financial Results
I'm PortAI, I can summarize articles.
Minerva Neurosciences (NERV) reported its Q3 2025 financial results, revealing a net loss of $9.76 million for the nine months ending September 30, 2025, compared to a net income of $5.71 million in the same period last year. The loss is attributed to increased R&D expenses and lack of significant other income. The company is focused on advancing its clinical trials for its lead product, roluperidone, despite facing regulatory challenges, including a Complete Response Letter from the FDA. Minerva plans to resubmit its NDA and is exploring strategic options to enhance shareholder value.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments